Delta variant surges across U.S. South; political leaders clamp down again
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Goldman Sachs tech conference highlights AI spending outlook
- Dell shares surge on record AI server bookings
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- 'No panic anywhere' may be the problem, BofA strategists warn
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Moderna, Inc’s (MRNA) mRNA-1345 Fast Track Designation is Encouraging; Peak Sales Up to $2.12B - Analyst
August 3, 2021 2:38 PM EDTEarlier today, Moderna, Inc., (NASDAQ: MRNA) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for mRNA-1345, its investigational single-dose mRNA vaccine against respiratory syncytial virus (RSV) in adults older than 60 years of... More
BioNTech (BNTX) PT Raised to $400 at Berenberg (Earlier)
August 2, 2021 1:43 PM EDTBerenberg analyst Shanshan Xu raised the price target on BioNTech (NASDAQ: BNTX) to $400.00 (from $325.00) while maintaining a Buy rating.
The analyst commented, "Given the emerging data, we think a COVID-19 vaccine booster is likely required for the containment of the virus and... More
